Carmot

Roche is ‘on par’ with Novo, Lilly in GLP-1 race after $2.7B Carmot deal
Medical Devices and Diagnostics Industry
Fri, 01/12/24 - 11:33 am
Roche
Carmot
GLP-1 agonist. obesity
Novo Nordisk
Eli Lilly